Newron Pharmaceuticals Statistics

Total Valuation

Newron Pharmaceuticals has a market cap or net worth of CHF 171.43 million. The enterprise value is 206.73 million.

Market Cap	171.43M
Enterprise Value	206.73M

Important Dates

The last earnings date was Friday, December 20, 2024.

Earnings Date	Dec 20, 2024
Ex-Dividend Date	n/a

Share Statistics

Newron Pharmaceuticals has 19.46 million shares outstanding. The number of shares has increased by 2.01% in one year.

Current Share Class	n/a
Shares Outstanding	19.46M
Shares Change (YoY)	+2.01%
Shares Change (QoQ)	+4.02%
Owned by Insiders (%)	5.53%
Owned by Institutions (%)	5.62%
Float	18.38M

Valuation Ratios

PE Ratio	n/a
Forward PE	8.46
PS Ratio	23.90
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-11.40
EV / Sales	30.81
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-16.05

Financial Position

The company has a current ratio of 3.73

Current Ratio	3.73
Quick Ratio	3.28
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	-3.65
Interest Coverage	-3.47

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-33.24%
Return on Capital (ROIC)	-42.51%
Revenue Per Employee	305,039
Profits Per Employee	-824,130
Employee Count	22
Asset Turnover	0.25
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +77.98% in the last 52 weeks. The beta is 0.70, so Newron Pharmaceuticals's price volatility has been lower than the market average.

Beta (5Y)	0.70
52-Week Price Change	+77.98%
50-Day Moving Average	7.95
200-Day Moving Average	8.27
Relative Strength Index (RSI)	61.43
Average Volume (20 Days)	102,313

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Newron Pharmaceuticals had revenue of CHF 6.71 million and -18.13 million in losses. Loss per share was -1.00.

Revenue	6.71M
Gross Profit	6.71M
Operating Income	-14.45M
Pretax Income	-18.11M
Net Income	-18.13M
EBITDA	-14.32M
EBIT	-14.45M
Loss Per Share	-1.00

Full Income Statement

Balance Sheet

The company has 11.73 million in cash and 47.03 million in debt, giving a net cash position of -35.30 million or -1.81 per share.

Cash & Cash Equivalents	11.73M
Total Debt	47.03M
Net Cash	-35.30M
Net Cash Per Share	-1.81
Equity (Book Value)	-29.69M
Book Value Per Share	-1.56
Working Capital	14.16M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -12.87 million and capital expenditures -9,628, giving a free cash flow of -12.88 million.

Operating Cash Flow	-12.87M
Capital Expenditures	-9,628
Free Cash Flow	-12.88M
FCF Per Share	-0.66

Full Cash Flow Statement

Margins

Gross margin is 100.00%, with operating and profit margins of -215.29% and -270.17%.

Gross Margin	100.00%
Operating Margin	-215.29%
Pretax Margin	-269.80%
Profit Margin	-270.17%
EBITDA Margin	-213.41%
EBIT Margin	-215.29%
FCF Margin	n/a

Dividends & Yields

Newron Pharmaceuticals does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-2.01%
Shareholder Yield	-2.01%
Earnings Yield	n/a
FCF Yield	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Newron Pharmaceuticals has an Altman Z-Score of -0.43. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.43
Piotroski F-Score	n/a